Here are the DEF 14A proxy statements from Alzamend Neuro, Inc. (ALZN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ALZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALZN filings page.
Alzamend Neuro is asking stockholders to vote at its virtual 2026 annual meeting on April 17, 2026 at 12:00 p.m. Eastern time. Stockholders will elect seven directors, ratify Haskell & White LLP as auditor, and give a non-binding advisory vote on executive compensation.
They are also asked to approve a 2025 Stock Incentive Plan covering 1.6 million shares of common stock and separate equity issuances to directors and executive officers. As of the February 25, 2026 record date, 3,804,741 shares of common stock were outstanding, with a 35% quorum requirement.
Another key proposal would amend the certificate of incorporation to authorize a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-10, at the Board’s discretion any time before April 16, 2027. A final proposal would permit adjournments of the meeting to solicit additional proxies. The Board recommends voting FOR all seven proposals.